These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9322088)

  • 1. Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion.
    Zaretsky JZ; Candotti F; Boerkoel C; Adams EM; Yewdell JW; Blaese RM; Plotz PH
    Hum Gene Ther; 1997 Sep; 8(13):1555-63. PubMed ID: 9322088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation.
    Nicolino MP; Puech JP; Kremer EJ; Reuser AJ; Mbebi C; Verdière-Sahuqué M; Kahn A; Poenaru L
    Hum Mol Genet; 1998 Oct; 7(11):1695-702. PubMed ID: 9736771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
    Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
    Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
    Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of glycogenosis type 2 by muscle-specific lentiviral vector.
    Richard E; Douillard-Guilloux G; Batista L; Caillaud C
    In Vitro Cell Dev Biol Anim; 2008; 44(10):397-406. PubMed ID: 18810562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy.
    Martin-Touaux E; Puech JP; Château D; Emiliani C; Kremer EJ; Raben N; Tancini B; Orlacchio A; Kahn A; Poenaru L
    Hum Mol Genet; 2002 Jul; 11(14):1637-45. PubMed ID: 12075008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY; Ho CH; Hsieh YH; Kikuchi T
    Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
    Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice.
    Ding EY; Hodges BL; Hu H; McVie-Wylie AJ; Serra D; Migone FK; Pressley D; Chen YT; Amalfitano A
    Hum Gene Ther; 2001 May; 12(8):955-65. PubMed ID: 11387060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
    Fuller M; Van der Ploeg A; Reuser AJ; Anson DS; Hopwood JJ
    Eur J Biochem; 1995 Dec; 234(3):903-9. PubMed ID: 8575451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
    McVie-Wylie AJ; Ding EY; Lawson T; Serra D; Migone FK; Pressley D; Mizutani M; Kikuchi T; Chen YT; Amalfitano A
    J Gene Med; 2003 May; 5(5):399-406. PubMed ID: 12731088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction.
    Ding E; Hu H; Hodges BL; Migone F; Serra D; Xu F; Chen YT; Amalfitano A
    Mol Ther; 2002 Apr; 5(4):436-46. PubMed ID: 11945071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.
    Mah C; Cresawn KO; Fraites TJ; Pacak CA; Lewis MA; Zolotukhin I; Byrne BJ
    Gene Ther; 2005 Sep; 12(18):1405-9. PubMed ID: 15920463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle.
    Van der Ploeg AT; Loonen MC; Bolhuis PA; Busch HM; Reuser AJ; Galjaard H
    Pediatr Res; 1988 Jul; 24(1):90-4. PubMed ID: 2970619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.
    Cresawn KO; Fraites TJ; Wasserfall C; Atkinson M; Lewis M; Porvasnik S; Liu C; Mah C; Byrne BJ
    Hum Gene Ther; 2005 Jan; 16(1):68-80. PubMed ID: 15703490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.